tbuckley/cabot-search huggingface dataset:
FRI0562 Attrition and Participant Characteristics in A Rheumatoid Arthritis Cohort
Authors: A. Cesta, X. Li, M. Tatangelo, C. Bombardier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The generalizability and validity of longitudinal observational studies is contingent on participant characteristics. If attrition is not random, it is important to identify any systematic differences between patients who continue to participate versus those who drop out. <h3>Objectives</h3> The purpose of this analysis was to compare characteristics of rheumatoid arthritis (RA) patients who continue to participate in the Ontario Best Practices Research Initiative (OBRI) to those of patients who have dropped out prior to reaching their 3 yr follow up. <h3>Methods</h3> Currently, 61 rheumatologists in Ontario (51% of active rheumatologists in Ontario) recruit patients into the OBRI. As of January 2015, 1533 patients had consented and were eligible to participate. 175 (11.4%) patients dropped out before reaching their 3 yr follow up assessment. Among the drop outs, 109 (7.1%) withdrew consent, 38 (2.5%) were lost to follow up, and 28 (1.8%) refused to reconsent after 2 yrs of follow up. In addition to the drop outs, 38 (2.5%) patients had died. 1320 (86.1%) patients remained active participants. Patient characteristics and disease activity at enrollment were compared in the 175 patients who dropped out versus the 1320 patients who continued to participate. A survival curve was generated to look at time of drop out over the 3 year follow up period. <h3>Results</h3> Compared to patients who dropped out, patients who continued to participate had higher household incomes, lower disease activity scores, and were more likely to be taking a biologic at the time of enrollment (Table 1). The survival curve shows that the majority of patients drop out within the first two years (Figure 1). <h3>Conclusions</h3> Patients with higher disease activity at enrollment were more likely to drop out. The OBRI attrition rate was 11.4% during the first three years of follow up, with 4.7% of patients dropping out in the first year, 3.5% in the second year and 3.2% in the third year. OBRI attrition rates were lower than those reported in the BRASS cohort (4.31% per 6 month follow up cycle) 1 and the ARAMIS cohort (6% per year) 2. The lower number of drop outs in the OBRI cohort could be attributed to the time invested in rheumatologist site visits by our study monitors and the biannual followup by our OBRI telephone interviewers. <h3>References</h3> Iannaccone et al., Arthritis Care &amp;Research, July 2013 Reisine et al., American College of Rheumatology, February 2000 <h3>Acknowledgement</h3> OBRI Investigators <h3>Disclosure of Interest</h3> None declared
OP0036 Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comparison of The Predictive Accuracy of Various Algorithms: Table 1.
Authors: A. Young, V. Nagaraja, S. Visovatti, V. McLaughlin, D. Khanna
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc) and has a 3 year survival rate of approximately 50%. Early screening for PAH in SSc may improve survival. <h3>Objectives</h3> To compare the predictive accuracy of two SSc-PAH screening algorithms, DETECT and Australian Scleroderma Interest Group (ASIG), to the 2009 European Society of Cardiology/European Respiratory Society (ESC/ERS) screening recommendations in a well-defined North American cohort. <h3>Methods</h3> Consecutive SSc patients with suspected PAH according to the 2013 recommendations for screening PAH (1) undergoing right heart catheterization (RHC) were evaluated. Those patients with no pulmonary hypertension or PAH on RHC who also had clinical variables available for applying the various screening algorithms had DETECT (2), ASIG (3) and 2009 ESC/ERS (4) screening algorithms applied. For each model, contingency table analysis was used to determine sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) for PAH [defined as mean pulmonary artery pressure (mPAP) &gt; or =25, pulmonary capillary wedge pressure (PCWP) &lt; or =15, and no/mild interstitial lung disease (ILD) on high-resolution CT scan of chest (HRCT), or FVC &gt; or =70%]. <h3>Results</h3> A total of 108 patients were screened for PAH, 77 of those patients met the recommendations for RHC, and 65 of those patients underwent RHC. The prevalence of PAH was 17%. Those patients with RHC values indicating no PH (N=35) or PAH (N=11) who also had biochemical markers available for review were identified and DETECT, ASIG, and ESC/ERS algorithms were applied to all of those patients. Those patients who met inclusion/exclusion criteria for DETECT and ASIG were also separately evaluated. DETECT and ASIG both had similar performances with sensitivity of 100% for those who met the respective inclusion/exclusion criteria. ESC/ERS had a sensitivity of 80% (Table 1). <h3>Conclusions</h3> In a well-defined North American cohort, DETECT and ASIG performed similarly and were superior to 2009 ESC/ERS screening recommendations in the detection of PAH in SSc patients. Many patients who are at-risk for PAH did not meet the inclusion/exclusion criteria for DETECT and ASIG in our cohort. <h3>References</h3> Khanna D et al. Arthritis Rheum. 2013 Dec; 65(12):3194–201. Coghlan JG et al. Ann Rheum Dis. 2014 Jul;73(7):1340–9. Thakkar V et al. Arthritis Res Ther. 2012 Jun 12;14(3):R143. Galie N et al. Eur Heart J. 2009 Oct; 30 (20):2493–537 <h3>Acknowledgement</h3> Supported by NIH/MIAMS K24 AR063120 <h3>Disclosure of Interest</h3> A. Young: None declared, V. Nagaraja: None declared, S. Visovatti: None declared, V. McLaughlin: None declared, D. Khanna Grant/research support from: Bayer, BMS, Consultant for: Actelion, Gilead, Bayer
Statins—Almost 30 Years of Use in the United States and Still Not Quite There
Authors: Robert A. Harrington
Journal: JAMA Cardiology (2016)

Joseph A. Salami, MD, MPH; Haider Warraich, MD; Javier Valero-Elizondo, MD, MPH; Erica S. Spatz, MD, MHS; Nihar R. Desai, MD, MPH; Jamal S. Rana, MD, PhD; Salim S. Virani, MD, PhD; Ron Blankstein, MD; Amit Khera, MD; Michael J. Blaha, MD, MPH; Roger S. Blumenthal, MD; Donald Lloyd-Jones, MD, ScM; Khurram Nasir, MD, MPH
Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS)
Authors: Charles Herbaux, Nicolas Duployez, Catherine Badens, Nicolas Poret, Claude Gardin, Virginie Eclache, Sylvie Daliphard, Anne Murati, Pascale Cony-Makhoul, Stephane Cheze, Blandine Beve, Thomas Prebet, Mathilde Hunault-Berger, Aline Renneville, Martin Figeac, Aspasia Stamatoullas, Christian Bastard, Pierre Fenaux, Claude Preudhomme, Christian Rose
Journal: Blood (2014)
Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.
Authors: Martin C. Müller, Philipp Erben, Thomas Schenk, Stephanie Lauber, Jens Kruth, Jana Hoffmann, Thomas Ernst, Tanja Lahaye, Georgia Metzgeroth, Michael Acevedo, Claude Nicaise, Rudiger Hehlmann, Andreas Hochhaus
Journal: Blood (2006)
Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self-Assessed Physical and Mental Health than cGVHD Patients without BOS
Authors: Lana Grkovic, Drazen Pulanic, Seth M. Steinberg, Kirsten M. Williams, Kristin Baird, Sandra A. Mitchell, Edward W. Cowen, Manuel B. Datiles, Carol W. Bassim, Joe Galen, Leora Comis, Daniele N. Avila, Tiffani N. Taylor, Dan Zhang, Kristen Cole, Dan H. Fowler, Frances T. Hakim, Ronald E. Gress, Steven Z. Pavletic
Journal: Blood (2012)
SP0080 Imaging in Early Detection of RA Joint Damage. What Technique and How To Use?
Authors: S. Finzel
Journal: Annals of the Rheumatic Diseases (2016)

Bone erosion is a characteristic of rheumatoid arthritis. Commonly, erosion is not only used to monitor radiographic progression over time as well as therapy efficaciousness, it also helps to correctly diagnose the disease. However, there are further signs of pathological bone alterations and inflammation such as periarticular loss of bone structure, and bone marrow edema. Nowadays, treatment and diagnostic strategies do not only aim at tight disease control and treat to remission, but to diagnose rheumatoid arthritis already at a very early stage of the disease and to detect alterations in bone even before erosion have occurred. The session will give an overview of the available modern imaging techniques, and of their strengths and weaknesses; after the session, the participant will have a clearer impression of when to use which imaging modality. <h3>Disclosure of Interest</h3> None declared
Role of cytochrome c in α-synuclein radical formation: implications of α-synuclein in neuronal death in Maneb- and paraquat-induced model of Parkinson’s disease
Authors: Ashutosh Kumar, Douglas Ganini, Ronald P. Mason
Journal: Molecular Neurodegeneration (2016)

The pathological features of Parkinson's disease (PD) include an abnormal accumulation of α-synuclein in the surviving dopaminergic neurons. Though PD is multifactorial, several epidemiological reports show an increased incidence of PD with co-exposure to pesticides such as Maneb and paraquat (MP). In pesticide-related PD, mitochondrial dysfunction and α-synuclein oligomers have been strongly implicated, but the link between the two has not yet been understood. Similarly, the biological effects of α-synuclein or its radical chemistry in PD is largely unknown. Mitochondrial dysfunction during PD pathogenesis leads to release of cytochrome c in the cytosol. Once in the cytosol, cytochrome c has one of two fates: It either binds to apaf1 and initiates apoptosis or can act as a peroxidase. We hypothesized that as a peroxidase, cytochrome c leaked out from mitochondria can form radicals on α-synuclein and initiate its oligomerization. Samples from controls, and MP co-exposed wild-type and α-synuclein knockout mice were studied using immuno-spin trapping, confocal microscopy, immunohistochemistry, and microarray experiments. Experiments with MP co-exposed mice showed cytochrome c release in cytosol and its co-localization with α-synuclein. Subsequently, we used immuno-spin trapping method to detect the formation of α-synuclein radical in samples from an in vitro reaction mixture consisting of cytochrome c, α-synuclein, and hydrogen peroxide. These experiments indicated that cytochrome c plays a role in α-synuclein radical formation and oligomerization. Experiments with MP co-exposed α-synuclein knockout mice, in which cytochrome c-α synuclein co-localization and interaction cannot occur, mice showed diminished protein radical formation and neuronal death, compared to wild-type MP co-exposed mice. Microarray data from MP co-exposed wild-type and α-synuclein knockout mice further showed that the absence of α-synuclein per se or its co-localization with cytochrome c confers protection from MP co-exposure, as several important pathways were unaffected in α-synuclein knockout mice. Altogether, these results show that peroxidase activity of cytochrome c contributes to α-synuclein radical formation and oligomerization, and that α-synuclein, through its co-localization with cytochrome c or on its own, affects several biological pathways which contribute to increased neuronal death in an MP-induced model of PD.
Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma.
Authors: Lan V Pham, Alex Rollo, Archito T. Tamayo, John Lee, Zhuang Zuo, Luhong Sun, Liang Zhang, Zhishou Ou, Luis E Fayad, Michael Wang, Richard J. Ford
Journal: Blood (2012)
Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin.
Authors: M. A. Blazer, J. Reardon, D. Efries, Y. T. Smith, L. M. Weatherby, K. Juergens, T. Criswell, J. S. Rose, G. S. Phillips, N. Griffith, T. S. Bekaii-Saab
Journal: Journal of Clinical Oncology (2011)

9079 Background: In moderately emetogenic regimens, palonosetron provides complete control of chemotherapy-induced nausea/vomiting (CINV) in 69.3% of patients [Grall, et al. Ann Oncol.14:2003, 1570-77]. Given this promising outcome, we hypothesized that adding palonosetron to our first-line prevention anti-emetic regimen will significantly increase complete control rate of CINV. Methods: Beginning August 2009, all patients starting a fluoropyrimidine-based regimen containing irinotecan (FOLFIRI or XELIRI) or oxaliplatin (FOLFOX or XELOX) received palonosetron at 0.25 mg and dexamethasone 12 mg prior to chemotherapy on day #1. Prior to August 2009, our standard consisted of ondansetron 16 mg and dexamethasone 12 mg prior to chemotherapy on day#1. Failure was defined as grade ≥ 1 vomiting or grade ≥ 2 nausea on days 1 to 5 post chemotherapy. In the event of failure, patients received Aprepitant (125 mg on day 1 and 80 mg on days 2 and 3) plus dexamethasone at 8 mg on days 2 through 4. In this retrospective review, patients were divided into pre-palonosetron (PRE) and post-palonosetron (POST) cohorts. Fisher’s exact test compared cohort differences while the Holm’s method adjusted the p-values to control the type I error rate at 5%. Results: 305 patients were included: 157 from PRE (median age: 55, range: 25-84) and 148 from POST (median age: 58, range: 28-84) cohorts. More than 80% of patients had advanced colorectal cancer. For all patients, risk of failure (RF) was reduced from 50.3% (CI 42.2, 58.4) to 28.4% (CI 21.3, 36.4) with the addition of palonosetron (p < 0.001). For the irinotecan-based cohort (PRE: N=79 and POST: N=56) RF was reduced from 55.7% (CI 44.1, 66.9) to 28.6% (CI 17.3, 42.2) (p = 0.006); and for the oxaliplatin-based cohort (PRE: N=78 and POST: N=92) RF was reduced from 44.9% (CI 33.6, 56.6) to 28.3% (CI 19.4, 38.6) with the addition of palonosetron (p = 0.026). Conclusions: The addition of palonosetron for the prevention of CINV significantly reduced the RF in patients receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin. This should be considered a standard practice when using these regimens.
Differences in the Angiogenic Response and Subsequent Growth of Plasma Cells From Myeloma and MGUS Patients Xenografted Into Zebrafish Embryos.
Authors: Dongdong Ma, Aravind Ramachandran, Yali Chang, Jianhong Lin, Weihong Zhang, Yu-Tzu Tai, Nikhil C. Munshi, Robert I Handin
Journal: Blood (2012)
Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine
Authors: Aditi Shastri, Carolina Schinke, Asya Varshavsky Yanovsky, Tushar D. Bhagat, Orsolya Giricz, Laura Barreyro, Jacqueline Boultwood, Andrea Pellagati, Yiting Yu, Jennifer R. Brown, David A. Frank, Bhaskar Das, Suman Kambhampati, Britta Will, Ulrich Steidl, Amit Verma
Journal: Blood (2014)
Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).
Authors: Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Gudrun Göhring, Brigitte Schlegelberger, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2009)
Clinical feature in adolescent and young adult with suspected carcinoma of unknown primary
Authors: Asuka Kawachi, Makoto Koudaira, Yuko Tanabe, Jyun Hashimoto, Mayu Yunokawa, Harukaze Yamamoto, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura
Journal: Annals of Oncology (2015)
Genetic Polymorphisms in the Homocysteine Metabolism Pathway and Thrombosis in Thai Children: A Case Control Study.
Authors: Nongnuch Sirachainan, Pornsri Tapanapruksakul, Werasak Sasanakul, Anannit Visudtibhan, Pimlak Charoenkwan, Praguywan Kadegasem, Umaporn Udomtrupayakul, Ampaiwan Chuansumrit
Journal: Blood (2006)
ABCG2 and SLC22A1 Expression Are Associated with Imatinib Response in Chronic Myeloid Leukemia
Authors: Douglas Vivona, Luciene Terezina Lima, Carolina Tosin Bueno, Rosario D C Hirata, Mario H Hirata, André Ducati Luchessi, Maria Zanichelli, Carlos S Chiattone, Elvira Maria Guerra-Shinohara
Journal: Blood (2011)
Experience with Autologous HSC Transplant in Therapy-Related MDS/AML Using Cells Harvested Prior to the Development of the Secondary Malignancy.
Authors: Luciano J. Costa, Vilmarie Rodriguez, Luis F. Porrata, Martha Q. Lacy, Michelle A. Elliott, Ayalew Tefferi, John A. Lust, Louis Letendre, Joseph P. Colgan, Morie A. Gertz, Dennis A. Gastineau, Mark R. Litzow
Journal: Blood (2007)
First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study
Authors: Godelieve Meunier, Loïc Ysebaert, Phi Linh Nguyen-Thi, Stephane Lepretre, Anne Quinquenel, Jehan Dupuis, Richard Lemal, Therese Aurran-Schleinitz, Cecile Tomowiak, Florence Cymbalista, Marie Sarah Dilhuydy, Annie Brion, Pierre Morel, Bruno Cazin, Veronique Leblond, Guillaume Cartron, Daniel Ré, Marie C Bene, Anne-Sophie Michallet, Pierre Feugier
Journal: Blood (2015)
SAT0116 Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Authors: J. Avouac, F. Amrouche, G. Rey, Y. Allanore
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on disease activity, severity and associated comorbidities. <h3>Objectives</h3> Our objective was to study the mortality profile of RA patients in France using multiple-cause-of-death analysis. <h3>Methods</h3> Data were collected between 2000 and 2011 in the French Epidemiological Center for the Medical Causes of Death database, and death certificates issued upon the death of an adult for whom RA was an underlying cause of death (UCD) or a non-underlying cause of death (NUCD) were evaluated using multiple-cause-of-death analysis. Sex, age, sex ratio, standardized mortality rates, as well as frequency of the various causes of death were assessed. For the main causes of death, the observed number of deaths in relation to the expected number of deaths (O:E ratio) was calculated. <h3>Results</h3> During the study period, 13,208 deaths related to RA were identified. RA was identified as the UCD in 4597 (35%) certificates. The number of certificates mentioning RA as the UCD decreased from 38 to 27% between 2000 and 2011. The mean±SD age at death was 79 ± 9 years (51% with ≥80 years). The female: male ratio was 3.2 and remained stable during the follow-up period. This ratio was significantly higher in the population where RA was the UCD (4.1 vs. 2.8 p&lt;0.001). The mean standardized mortality rate was 0.25 per 1 million people (range 0.21–0.28), and remained stable throughout the period. When RA was the UCD (n=4,597), the main NUCDs were cardiovascular diseases (29%) and infectious diseases (22%). When RA was a NUCD (n=8,611), the most common UCDs were cardiovascular diseases (35% of certificates, including 877 patients with ischemic heart disease), neoplasms (15%), respiratory diseases (10%) and infectious diseases (7%). The overall O:E ratio was &gt;1 for infectious (3.56), respiratory (1.40) and cardiovascular diseases (1.24), but was &lt;1 for neoplasms. <h3>Conclusions</h3> This is the first national study using a multiple-cause-of-death analysis to study the mortality profile of patients with RA. Our results show that cardiovascular diseases are the most common UCD and NUCD associated with RA in France. These data strengthen the need to develop specific strategies for cardiovascular prevention to improve survival of patients with RA. <h3>Disclosure of Interest</h3> None declared
High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma
Authors: Kimon V. Argyropoulos, Steven M Horwitz, Franck Rapaport, Enrico Velardi, Patricia Myskowski, Christiane Querfeld, Melissa Pulitzer, Ahmet Dogan, Meighan Gallagher, Nicholas D. Socci, Ross L. Levine, Minal Patel, Natasha Galasso, Marcel van den Brink, Lia Palomba
Journal: Blood (2015)
Genetic Loss of NFAT2 Induces Profound Acceleration of CLL in the TCL1 Mouse Model
Authors: Melanie Märklin, Stefanie Bugl, Jonas S. Heitmann, Alexandra Poljak, Bettina S, Hans-Georg Kopp, Lothar Kanz, Anjana Rao, Stefan Wirths, Martin R Müller
Journal: Blood (2012)
Experiments on the Destruction of Lice and Nits. Experiments concerning the Destruction of Active Lice (Pcdiculus humane) by Solutions of Cresol Soap Emulsion and Lysol, and of Lice and Nits with Kerosene, with a View to the Use of these Remedies for the Treatment of Verminous Heads.
Authors: A. Bacot, L. Lloyd
Journal: BMJ (1919)
P1204 : Genomic T cell receptor signatures in matched gut, liver and blood samples from primary sclerosing cholangitis patients
Authors: E.K. Klemsdal Henriksen, K. Kaasen Jørgensen, K. Holm, J. Olweus, K. Muri Boberg, G. Hirschfield, T.H. Karlsen, E. Liaskou
Journal: Journal of Hepatology (2015)
Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
Authors: Maria Corinna Palanca-Wessels, Gilles Andre Salles, Myron S. Czuczman, Sarit E. Assouline, Ian W. Flinn, Laurie H. Sehn, Manish Patel, Randeep Sangha, Herve Tilly, Ranjana Advani, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Akiko Chai, Yu-Waye Chu, Franck Morschhauser
Journal: Blood (2013)
Pkc Epsilon Regulates Mitochondrial Redox Biology to Support the Differentiation Blockade in Acute Myeloid Leukemia
Authors: Daniela Di Marcantonio, Jessica Vadaketh, Esteban Martinez, Prisco Mirandola, Giuliana Gobbi, Michael D. Milsom, Claudia Scholl, Stefan Fröhling, Marco Vitale, Stephen Matthew Sykes
Journal: Blood (2015)
Involvement of Fanconi Anemia (FA) Genes FANCG and FANCA in Human DNA Replication, Mitosis and Chromosome Segregation: A Gene Expression Profiling Study.
Authors: Ph. Guardiola, P. Ladne, J. Soulier, F. Siclon, J. Delrow, E. Gluckman, F. Sigaux, J.P. Radich
Journal: Blood (2004)
Overexpression of Par-4 Increases TRAIL-Induced Apoptosis in Neoplastic Lymphocytes by Diminishing Expression of Inhibitors-of-Apoptosis-Proteins and by Enforcing Activation of Initiator- and Executionercaspases.
Authors: Simone Boehrer, Daniel Nowak, Dieter Hoelzer, Paris S. Mitrou, Kai Uwe Chow
Journal: Blood (2004)
Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms
Authors: Brittney Dienes, Bartlomiej P Przychodzen, Michael Clemente, Wenyi Shen, Chantana Polprasert, Naoko Hosono, Satoru Miyano, Yuichi Shiraishi, Kenichi Yoshida, Seishi Ogawa, Mikkael A. Sekeres, Yogen Saunthararajah, Jaroslaw P. Maciejewski, Hideki Makishima
Journal: Blood (2014)